Switch theme
Sign up to access all valuation multiples
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business.
1998
2.1K+
LTM Revenue $860M
LTM EBITDA $425M
$5.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Beijing Tiantan has a last 12-month revenue of $860M and a last 12-month EBITDA of $425M.
In the most recent fiscal year, Beijing Tiantan achieved revenue of $831M and an EBITDA of $397M.
Beijing Tiantan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Beijing Tiantan valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $714M | $831M | XXX | XXX | XXX |
| Gross Profit | $288M | $362M | XXX | XXX | XXX |
| Gross Margin | 40% | 44% | XXX | XXX | XXX |
| EBITDA | $285M | $397M | XXX | XXX | XXX |
| EBITDA Margin | 40% | 48% | XXX | XXX | XXX |
| Net Profit | $121M | $153M | XXX | XXX | XXX |
| Net Margin | 17% | 18% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Beijing Tiantan's stock price is CNY 22 (or $3).
Beijing Tiantan has current market cap of CNY 43.7B (or $6.0B), and EV of CNY 41.1B (or $5.7B).
See Beijing Tiantan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.7B | $6.0B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Beijing Tiantan has market cap of $6.0B and EV of $5.7B.
Beijing Tiantan's trades at 6.6x LTM EV/Revenue multiple, and 13.3x LTM EBITDA.
Analysts estimate Beijing Tiantan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Beijing Tiantan and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.7B | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | XXX | XXX |
| EV/EBITDA | 14.2x | XXX | XXX | XXX |
| P/E | 28.2x | XXX | XXX | XXX |
| P/E/Growth | 2.8x | XXX | XXX | XXX |
| EV/FCF | -165.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBeijing Tiantan's NTM/LTM revenue growth is 12%
Beijing Tiantan's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Beijing Tiantan's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Beijing Tiantan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Beijing Tiantan and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 39% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 60% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 13% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Beijing Tiantan acquired XXX companies to date.
Last acquisition by Beijing Tiantan was XXXXXXXX, XXXXX XXXXX XXXXXX . Beijing Tiantan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Beijing Tiantan founded? | Beijing Tiantan was founded in 1998. |
| Where is Beijing Tiantan headquartered? | Beijing Tiantan is headquartered in China. |
| How many employees does Beijing Tiantan have? | As of today, Beijing Tiantan has 2.1K+ employees. |
| Is Beijing Tiantan publicy listed? | Yes, Beijing Tiantan is a public company listed on SHG. |
| What is the stock symbol of Beijing Tiantan? | Beijing Tiantan trades under 600161 ticker. |
| When did Beijing Tiantan go public? | Beijing Tiantan went public in 1998. |
| Who are competitors of Beijing Tiantan? | Similar companies to Beijing Tiantan include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Beijing Tiantan? | Beijing Tiantan's current market cap is $6.0B |
| What is the current revenue of Beijing Tiantan? | Beijing Tiantan's last 12-month revenue is $860M. |
| What is the current EBITDA of Beijing Tiantan? | Beijing Tiantan's last 12-month EBITDA is $425M. |
| What is the current EV/Revenue multiple of Beijing Tiantan? | Current revenue multiple of Beijing Tiantan is 6.6x. |
| What is the current EV/EBITDA multiple of Beijing Tiantan? | Current EBITDA multiple of Beijing Tiantan is 13.3x. |
| What is the current revenue growth of Beijing Tiantan? | Beijing Tiantan revenue growth between 2023 and 2024 was 16%. |
| Is Beijing Tiantan profitable? | Yes, Beijing Tiantan is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
